Gilead, HHS chief announce donation of HIV prevention drug Truvada

Modesto Morganelli
Mag 13, 2019

It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently. "Will help us achieve our goal of ending the HIV epidemic in America!" And despite officially holding the patent on preventive use of Truvada since 2015, it had struggled to reach a royalties agreement with Gilead, which has disputed the government's patent claim.

Up to 200,000 uninsured people may soon have access to a medication that prevents the transmission of HIV.

Gilead will donate Truvada until its second-generation HIV preventative medication, Descovy, becomes available.

Following Gilead's announcement, HHS Sec.

Gilead Sciences will donate emtricitabine/tenofovir disoproxil fumarate (Truvada), the only drug approved to prevent infection with HIV, to the United States in order to supply 200,000 patients annually for up to 11 years. It plans to extend its period of donations until 2030.

Truvada sells for about $1,600 to $2,000 a month in the U.S. Louisiana fell from third in HIV infection diagnosis rate in 2016 to fourth in 2017 with a decrease of 120 cases in that time frame, according to the CDC.

Carl Schmid, AIDS Institute deputy executive director, welcomed the donation from Gilead, stating that it would free up federal government spending that would otherwise be used on getting medication of uninsured people.

"We believe today's donation, combined with efforts to address the root causes of the epidemic, such as racism, violence against women, stigma, homophobia and transphobia, can play an important role in ending the HIV epidemic in the United States, particularly in parts of the country with the highest burden of disease". However, the House Appropriations Committee has approved almost $500 million in spending for disease treatment and prevention earlier this week.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE